Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed carcinoma arising from the pancreas~  * Stage II or III disease, meeting 1 of the following criteria:~    * Nonresectable disease~   * Potentially resectable disease~   * Resectable disease~ * Stage IV disease with symptomatic back pain requiring palliation allowed at the discretion of the principal investigator~* Measurable, evaluable, or nonmeasurable disease~* No neuroendocrine tumor of the pancreas~* No documented brain metastasis~* No clinically significant pleural or peritoneal effusions that cannot be drained~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9 g/dL~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver has tumor involvement)~* AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)~* Creatinine clearance ≥ 45 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No active infection~* No serious systemic disorders that would preclude study treatment~* No significant cardiovascular disease in the form of abnormal electrocardiogram coupled with clinical features of recent or recurrent cardiac disease (including myocardial infarction, angina, or hypertension)~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior investigational agents~* No prior chemotherapy for pancreatic cancer~* Must be able to discontinue aspirin, dexamethasone, and other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after pemetrexed disodium dose (5 days before for long-acting agents such as piroxicam)~* Must be able and willing to take folic acid and cyanocobalamin (vitamin B12) supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pemetrexed in combination with concomitant radiotherapy (Type: EXPERIMENTAL): Patients will receive Pemetrexed plus Radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).